Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ICH Opens Up Management Committee To Regulators From China, Singapore, South Korea

Executive Summary

The ICH has now largely finished implementing its structural and organizational reforms by adding new regulatory and industry members to the organization. The reform process aims to increase ICH's international outreach and turn it into a “truly global initiative.”

You may also be interested in...



ICH Evaluates Guideline Uptake By New And Old Members

The study will be undertaken by an independent third party and its results will help facilitate a transparent dialogue on the long-term goal of ensuring that all the ICH regulators implement all the ICH guidelines.

The Quality Lowdown: ICH Q13 and Q14, Gene Therapy CMC, Drug Shortage Gaps, And An Excipient Misstep

ICH launches continuous manufacturing and analytical procedure guidelines while US FDA promises advice on gene therapy CMC, battles drug shortages and sees what went wrong with certain eye injections.

'Historical Moment' As Global Generics Body Gets Seat On ICH Management Committee

The move recognizes the expertise that generic and biosimilar drug developers can bring to the scientific discussions at the International Council on Harmonisation. 

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS123368

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel